Cross-agency comparison: 🇪🇺 EMA leads with 82 documents in 90 days

FDA vs EMA vs MHRA vs Health Canada — who's most active?

The cross-agency pattern suggests Europe is currently the most active regulatory environment by a wide margin, with EMA output far exceeding MHRA, FDA, and Health Canada; this may indicate that sponsors targeting the EU should expect the densest volume of evolving expectations and the highest need for regulatory surveillance. By contrast, the lower but still meaningful output from FDA and Health Canada could suggest more selective change management, while the UK appears active enough to merit dedicated attention but not at the same scale as the EU. For global filing strategy, sponsors should consider front-loading intelligence and medical-regulatory writing resources into the EU-facing package, then aligning downstream adaptations for the US, UK, and Canada to reduce rework and avoid fragmented dossiers.